American Century Companies Inc. Has $37.40 Million Position in Encompass Health Co. (NYSE:EHC)

American Century Companies Inc. reduced its position in Encompass Health Co. (NYSE:EHC) by 3.0% in the 4th quarter, Holdings Channel reports. The firm owned 404,918 shares of the company’s stock after selling 12,734 shares during the quarter. American Century Companies Inc.’s holdings in Encompass Health were worth $37,395,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. TD Private Client Wealth LLC boosted its position in shares of Encompass Health by 2,870.0% during the 3rd quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company’s stock valued at $709,000 after acquiring an additional 7,089 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Encompass Health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock valued at $161,781,000 after purchasing an additional 20,547 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Encompass Health by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company’s stock worth $59,544,000 after buying an additional 4,345 shares during the period. Central Pacific Bank Trust Division boosted its stake in Encompass Health by 15.1% in the 4th quarter. Central Pacific Bank Trust Division now owns 3,195 shares of the company’s stock valued at $295,000 after buying an additional 418 shares in the last quarter. Finally, Merit Financial Group LLC bought a new stake in shares of Encompass Health in the 4th quarter worth about $374,000. Institutional investors own 97.25% of the company’s stock.

Insider Activity at Encompass Health

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares of the company’s stock, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.10% of the stock is owned by corporate insiders.

Encompass Health Trading Up 0.8 %

NYSE:EHC opened at $101.19 on Friday. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a 1-year low of $78.53 and a 1-year high of $104.55. The firm has a market capitalization of $10.19 billion, a price-to-earnings ratio of 22.69, a PEG ratio of 2.31 and a beta of 0.92. The business’s 50-day moving average price is $98.55 and its two-hundred day moving average price is $97.31.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. On average, equities analysts expect that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.67%. The ex-dividend date of this dividend is Tuesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is 15.25%.

Analyst Ratings Changes

EHC has been the topic of a number of research analyst reports. Barclays increased their price target on Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. William Blair restated an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a research report on Tuesday, February 11th. KeyCorp upped their price target on Encompass Health from $117.00 to $120.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Finally, StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, February 15th. Ten equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $107.67.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.